UBS Group Boosts Illumina (NASDAQ:ILMN) Price Target to $133.00

Illumina (NASDAQ:ILMN) had its price objective upped by UBS Group from $131.00 to $133.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a neutral rating on the life sciences company’s stock.

A number of other brokerages have also recently weighed in on ILMN. Citigroup raised Illumina from a neutral rating to a buy rating and set a $140.00 price objective for the company in a research note on Wednesday, July 10th. Evercore ISI reduced their price target on shares of Illumina from $195.00 to $175.00 and set an outperform rating on the stock in a research report on Tuesday, June 11th. Barclays raised their price target on shares of Illumina from $85.00 to $100.00 and gave the company an underweight rating in a research report on Wednesday, April 10th. StockNews.com assumed coverage on Illumina in a research report on Sunday, June 30th. They issued a buy rating on the stock. Finally, Royal Bank of Canada cut their target price on shares of Illumina from $249.00 to $242.00 and set an outperform rating on the stock in a research note on Monday, July 1st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $151.57.

Illumina Trading Down 2.5 %

ILMN traded down $3.14 during trading hours on Wednesday, reaching $123.56. The company’s stock had a trading volume of 1,860,377 shares, compared to its average volume of 2,122,721. The business’s 50-day moving average is $112.98 and its 200-day moving average is $123.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market cap of $19.68 billion, a PE ratio of -15.16 and a beta of 1.15. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $195.64.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.24. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. Illumina’s revenue was down 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.32 EPS. As a group, equities research analysts predict that Illumina will post 1.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. raised its stake in shares of Illumina by 22.6% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 8,576 shares of the life sciences company’s stock worth $1,194,000 after purchasing an additional 1,582 shares during the last quarter. Private Trust Co. NA grew its holdings in Illumina by 42.9% during the 4th quarter. Private Trust Co. NA now owns 756 shares of the life sciences company’s stock valued at $105,000 after buying an additional 227 shares during the last quarter. International Assets Investment Management LLC increased its position in Illumina by 210.5% during the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock worth $6,711,000 after buying an additional 32,672 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Illumina by 238.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 31,844 shares of the life sciences company’s stock worth $4,434,000 after acquiring an additional 22,425 shares during the last quarter. Finally, RFG Advisory LLC boosted its stake in shares of Illumina by 41.0% during the fourth quarter. RFG Advisory LLC now owns 3,267 shares of the life sciences company’s stock valued at $455,000 after acquiring an additional 950 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.